Ombitasvir/paritaprevir/ritonavir
(Redirected from Technivie)
Combination antiviral medication used to treat hepatitis C
| Drug Information | |||
|---|---|---|---|
| Image | 250 | ||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Ombitasvir/paritaprevir/ritonavir is a fixed-dose combination antiviral medication used in the treatment of hepatitis C, a viral infection that affects the liver. This combination is marketed under the brand names Viekira Pak and Technivie.
Medical uses[edit | edit source]
Ombitasvir/paritaprevir/ritonavir is primarily indicated for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotypes 1 and 4. It is often used in combination with dasabuvir and sometimes with ribavirin to enhance its efficacy.
Mechanism of action[edit | edit source]
The combination of ombitasvir, paritaprevir, and ritonavir works by targeting different stages of the HCV life cycle:
- Ombitasvir is an NS5A inhibitor that interferes with the viral replication process.
- Paritaprevir is an NS3/4A protease inhibitor that prevents the cleavage of the HCV polyprotein, which is essential for viral replication.
- Ritonavir acts as a pharmacokinetic enhancer by inhibiting the CYP3A enzyme, thereby increasing the plasma concentration of paritaprevir.
Side effects[edit | edit source]
Common side effects of this medication combination include fatigue, nausea, itching, and insomnia. More serious side effects can include liver problems, especially in patients with underlying liver disease.
Contraindications[edit | edit source]
This medication is contraindicated in patients with severe liver impairment and in those who are taking medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious adverse events.
Drug interactions[edit | edit source]
Due to the presence of ritonavir, a potent CYP3A inhibitor, ombitasvir/paritaprevir/ritonavir can interact with a wide range of medications. It is important to review all concomitant medications to avoid potential interactions.
History[edit | edit source]
Ombitasvir/paritaprevir/ritonavir was approved by the U.S. Food and Drug Administration (FDA) in 2014 as part of a combination therapy for the treatment of hepatitis C. It represented a significant advancement in the treatment of HCV, offering a more effective and tolerable option compared to previous therapies.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
